Augmedix Q2 2024 GAAP EPS $(0.16) Misses $(0.13) Estimate, Sales $13.664M Beat $13.636M Estimate
Portfolio Pulse from Benzinga Newsdesk
Augmedix (NASDAQ:AUGX) reported Q2 2024 GAAP EPS of $(0.16), missing the $(0.13) estimate, but achieved sales of $13.664M, beating the $13.636M estimate. Sales increased by 26.75% year-over-year.
August 12, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Augmedix reported a Q2 2024 GAAP EPS of $(0.16), missing the $(0.13) estimate by 23.08%. However, the company achieved sales of $13.664M, beating the $13.636M estimate and marking a 26.75% increase year-over-year.
The mixed results, with a significant EPS miss but a slight sales beat and strong year-over-year growth, are likely to have a neutral short-term impact on the stock price. Investors may weigh the EPS miss against the positive sales growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100